Importer of Controlled Substances Application: Medi-Physics, Inc. dba GE Healthcare, 2456-2457 [2021-00353]

Download as PDF 2456 Federal Register / Vol. 86, No. 7 / Tuesday, January 12, 2021 / Notices INTERNATIONAL TRADE COMMISSION [Investigation Nos. 701–TA–522 and 731– TA–1258 (Review)] Passenger Vehicle and Light Truck Tires From China; Scheduling of Expedited Five-Year Reviews United States International Trade Commission. ACTION: Notice. AGENCY: The Commission hereby gives notice of the scheduling of expedited reviews pursuant to the Tariff Act of 1930 (‘‘the Act’’) to determine whether revocation of the countervailing and antidumping duty orders on passenger vehicle and light truck tires from China would be likely to lead to continuation or recurrence of material injury within a reasonably foreseeable time. DATES: October 5, 2020. FOR FURTHER INFORMATION CONTACT: Alejandro Orozco (202–205–3177), Office of Investigations, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436. Hearing-impaired persons can obtain information on this matter by contacting the Commission’s TDD terminal on 202– 205–1810. Persons with mobility impairments who will need special assistance in gaining access to the Commission should contact the Office of the Secretary at 202–205–2000. General information concerning the Commission may also be obtained by accessing its internet server (https:// www.usitc.gov). The public record for these reviews may be viewed on the Commission’s electronic docket (EDIS) at https://edis.usitc.gov. SUPPLEMENTARY INFORMATION: Background.—On October 5, 2020, the Commission determined that the domestic interested party group response to its notice of institution (85 FR 39581, July 1, 2020) of the subject five-year reviews was adequate and that the respondent interested party group response was inadequate. The Commission did not find any other circumstances that would warrant conducting full reviews.1 Accordingly, the Commission determined that it would conduct expedited reviews pursuant to section 751(c)(3) of the Tariff Act of 1930 (19 U.S.C. 1675(c)(3)). For further information concerning the conduct of these reviews and rules of general application, consult the Commission’s Rules of Practice and Procedure, part 201, subparts A and B khammond on DSKJM1Z7X2PROD with NOTICES SUMMARY: 1 A record of the Commissioners’ votes is available from the Office of the Secretary and at the Commission’s website. VerDate Sep<11>2014 17:09 Jan 11, 2021 Jkt 253001 (19 CFR part 201), and part 207, subparts A, D, E, and F (19 CFR part 207). Please note the Secretary’s Office will accept only electronic filings at this time. Filings must be made through the Commission’s Electronic Document Information System (EDIS, https:// edis.usitc.gov). No in-person paperbased filings or paper copies of any electronic filings will be accepted until further notice. Staff report.—A staff report containing information concerning the subject matter of the reviews will be placed in the nonpublic record on January 8, 2021, and made available to persons on the Administrative Protective Order service list for these reviews. A public version will be issued thereafter, pursuant to section 207.62(d)(4) of the Commission’s rules. Written submissions.—As provided in section 207.62(d) of the Commission’s rules, interested parties that are parties to the reviews and that have provided individually adequate responses to the notice of institution,2 and any party other than an interested party to the reviews may file written comments with the Secretary on what determination the Commission should reach in the reviews. Comments are due on or before January 14, 2021 and may not contain new factual information. Any person that is neither a party to the five-year reviews nor an interested party may submit a brief written statement (which shall not contain any new factual information) pertinent to the reviews by January 14, 2021. However, should the Department of Commerce (‘‘Commerce’’) extend the time limit for its completion of the final results of its reviews, the deadline for comments (which may not contain new factual information) on Commerce’s final results is three business days after the issuance of Commerce’s results. If comments contain business proprietary information (BPI), they must conform with the requirements of sections 201.6, 207.3, and 207.7 of the Commission’s rules. The Commission’s Handbook on Filing Procedures, available on the Commission’s website at https:// www.usitc.gov/documents/handbook_ on_filing_procedures.pdf, elaborates 2 The Commission has found the response to its notice of institution filed by the United Steel, Paper and Forestry, Rubber, Manufacturing, Energy, Allied Industrial and Service Workers International Union (‘‘domestic interested party’’), which represents workers at five domestic producers of PVLT tires: Cooper Tire & Rubber Company, the Goodyear Tire & Rubber Company, Michelin North America Inc., Sumitomo Rubber USA, LLC, and the Yokohama Rubber Co., Ltd., to be adequate. Comments from other interested parties will not be accepted (see 19 CFR 207.62(d)(2)). PO 00000 Frm 00077 Fmt 4703 Sfmt 4703 upon the Commission’s procedures with respect to filings. In accordance with sections 201.16(c) and 207.3 of the rules, each document filed by a party to the reviews must be served on all other parties to the review (as identified by either the public or BPI service list), and a certificate of service must be timely filed. The Secretary will not accept a document for filing without a certificate of service. Determination.—The Commission has determined these reviews are extraordinarily complicated and therefore has determined to exercise its authority to extend the review period by up to 90 days pursuant to 19 U.S.C. 1675(c)(5)(B). Authority: These reviews are being conducted under authority of title VII of the Tariff Act of 1930; this notice is published pursuant to section 207.62 of the Commission’s rules. By order of the Commission. Issued: January 7, 2021. Lisa Barton, Secretary to the Commission. [FR Doc. 2021–00435 Filed 1–11–21; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–763] Importer of Controlled Substances Application: Medi-Physics, Inc. dba GE Healthcare Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: Medi-Physics, Inc. dba GE Healthcare has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before February 11, 2021. Such persons may also file a written request for a hearing on the application on or before February 11, 2021. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, SUMMARY: E:\FR\FM\12JAN1.SGM 12JAN1 2457 Federal Register / Vol. 86, No. 7 / Tuesday, January 12, 2021 / Notices Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. In accordance with 21 CFR 1301.34(a), this is notice that on December 15, 2020, Medi-Physics, Inc. dba GE Healthcare, 3350 North Ridge Avenue, Arlington Heights, Illinois 60004–1412, applied to be registered as an importer of the following basic class(es) of controlled substance(s): SUPPLEMENTARY INFORMATION: Controlled substance Cocaine ........................ Drug code 9041 Schedule II The company plans to import small quantities of Ioflupane, in the form of three separate analogues of Cocaine, to validate production and quality control systems, for a reference standard, and for producing material for a future investigational new drug submission. Supplies of this particular controlled substance are not available in the form needed within the current domestic supply of the United States. No other activity for this drug code is authorized for this registration. Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or nonapproved finished dosage forms for commercial sale. William T. McDermott, Assistant Administrator. [FR Doc. 2021–00353 Filed 1–11–21; 8:45 am] BILLING CODE P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–756] Bulk Manufacturer of Controlled Substances Application: Cedarburg Pharmaceuticals William T. McDermott, Assistant Administrator. Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: [FR Doc. 2021–00351 Filed 1–11–21; 8:45 am] Cedarburg Pharmaceuticals has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before March 15, 2021. Such persons may also file a written request for a hearing on the application on or before March 15, 2021. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on October 16, 2020, Cedarburg Pharmaceuticals 870 Badger Circle, Grafton, Wisconsin 53024, applied to be registered as a bulk manufacturer of the following basic class(es) of controlled substance(s): SUMMARY: Controlled substance Tetrahydrocannabinols 3, 4Methylenedioxymethamphetamine. Dimethyltryptamine ....... Psilocybin ..................... Methylphenidate ........... Nabilone ....................... 4-Anilino-N-phenethyl-4piperidine (ANPP). Fentanyl ........................ Drug code The company plans to manufacture bulk active pharmaceutical ingredients (API) for distribution to its customers. In reference to the drug code 7370 (Tetrahydrocannabinols), the company plans to bulk manufacture as synthetic. No other activity for this drug code is authorized for this registration. Schedule 7370 7405 I I 7435 7437 1724 7379 8333 I I II II II 9801 II BILLING CODE P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–765] Bulk Manufacturer of Controlled Substances Application: Organix, Inc. Drug Enforcement Administration, Justice. ACTION: Notice of application. AGENCY: Organix, Inc. has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information. DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before March 15, 2021. Such persons may also file a written request for a hearing on the application on or before March 15, 2021. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.33(a), this is notice that on September 22, 2020, Organix, Inc., 240 Salem Street, Woburn, Massachusetts 01801, applied to be registered as an bulk manufacturer of the following basic class(es) of controlled substance(s): SUMMARY: khammond on DSKJM1Z7X2PROD with NOTICES Controlled substance Drug code Gamma Hydroxybutyric Acid ........................................................................................................................................... Lysergic acid diethylamide .............................................................................................................................................. Marihuana ........................................................................................................................................................................ Tetrahydrocannabinols .................................................................................................................................................... 5-Methoxy-N-N-dimethyltryptamine ................................................................................................................................. Bufotenine ........................................................................................................................................................................ Dimethyltryptamine .......................................................................................................................................................... Psilocybin ......................................................................................................................................................................... Psilocyn ........................................................................................................................................................................... Heroin .............................................................................................................................................................................. VerDate Sep<11>2014 18:51 Jan 11, 2021 Jkt 253001 PO 00000 Frm 00078 Fmt 4703 Sfmt 4703 E:\FR\FM\12JAN1.SGM 12JAN1 2010 7315 7360 7370 7431 7433 7435 7437 7438 9200 Schedule I I I I I I I I I I

Agencies

[Federal Register Volume 86, Number 7 (Tuesday, January 12, 2021)]
[Notices]
[Pages 2456-2457]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-00353]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-763]


Importer of Controlled Substances Application: Medi-Physics, Inc. 
dba GE Healthcare

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

-----------------------------------------------------------------------

SUMMARY: Medi-Physics, Inc. dba GE Healthcare has applied to be 
registered as an importer of basic class(es) of controlled 
substance(s). Refer to Supplemental Information listed below for 
further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), 
and applicants therefore, may file written comments on or objections to 
the issuance of the proposed registration on or before February 11, 
2021. Such persons may also file a written request for a hearing on the 
application on or before February 11, 2021.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a 
hearing must be sent to: Drug Enforcement Administration, Attn: 
Administrator, 8701 Morrissette Drive, Springfield,

[[Page 2457]]

Virginia 22152. All requests for a hearing should also be sent to: (1) 
Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 
Morrissette Drive, Springfield, Virginia 22152; and (2) Drug 
Enforcement Administration, Attn: DEA Federal Register Representative/
DPW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this 
is notice that on December 15, 2020, Medi-Physics, Inc. dba GE 
Healthcare, 3350 North Ridge Avenue, Arlington Heights, Illinois 60004-
1412, applied to be registered as an importer of the following basic 
class(es) of controlled substance(s):

------------------------------------------------------------------------
                                           Drug
          Controlled substance             code          Schedule
------------------------------------------------------------------------
Cocaine................................     9041  II
------------------------------------------------------------------------

    The company plans to import small quantities of Ioflupane, in the 
form of three separate analogues of Cocaine, to validate production and 
quality control systems, for a reference standard, and for producing 
material for a future investigational new drug submission. Supplies of 
this particular controlled substance are not available in the form 
needed within the current domestic supply of the United States. No 
other activity for this drug code is authorized for this registration.
    Approval of permit applications will occur only when the 
registrant's business activity is consistent with what is authorized 
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import 
of Food and Drug Administration-approved or non-approved finished 
dosage forms for commercial sale.

William T. McDermott,
Assistant Administrator.
[FR Doc. 2021-00353 Filed 1-11-21; 8:45 am]
BILLING CODE P